Objective: Because the extracellular matrix protein agrin is essential for neuromuscular junction formation and maintenance, we tested the hypothesis that autoantibodies against agrin are present in sera from patients with myasthenia gravis (MG).
on the basis of clinical features and neurophysiologic investigations. The majority of the sera are identical to those described previously. 8 We used a total of 54 sera, 30 of which were sera without antibodies to the AChR or MuSK, 9 had elevated levels of anti-AChR antibodies, and 15 were from patients with MuSK-seropositive MG. In addition, one patient with a genetically confirmed lateonset Pompe disease was included for control purposes. 8 Sera from 16 healthy volunteers served as control. Sera were anonymized, and the experiments were performed double-blind.
Clinical information was graded according to the Myasthenia Gravis Foundation of America (MGFA) classification. 13 Analysis included demographic data, symptoms, and signs. The clinical data used for diagnosis, including presence of anti-AChR antibodies, repetitive nerve stimulation testing, treatment attempts, and treatment responses are summarized in the table.
Standard protocol approvals, registrations, and patient consents. All serum samples were obtained with the full consent of the patients and probands in accordance with the Declaration of Helsinki. The analysis of the sera has been approved by the Ethics Committee of the Ludwig-Maximilians University (project 184-08).
ELISA. Human mini-agrin complementary DNA (cDNA) was cloned into the pCEPPu BM40 vector containing an N-terminal BM40-derived signal sequence and a C-terminal 6xHis tag. 14 The cDNA encoding neural mini-agrin encompasses the NtA domain and one follistatin-like domain from the N-terminal part of the human agrin protein fused to the C-terminal part of agrin containing 4 EGF-like domains and 3 laminin-G-like domains with the A/y4 and B/z8 inserts. 14, 15 Mini-agrin was affinitypurified to homogeneity from the supernatant of transiently transfected 293HEK cells 36 hours after the transfection using the Protino Ni-TED 1000 system according to the manufacturer's instructions (Macherey-Nagel, Düren, Germany). Successful expression and purification was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequent Coomassie blue or silver staining as well as Western blotting. The purified mini-agrin was active in AChR aggregation on cultured C2C12 cells (data not shown).
Transparent 96-well ELISA plates (Greiner Bio-One GmbH, Frickenhausen, Germany) were coated with 100 mL of adsorption buffer (sodium carbonate buffer, pH 8.6) containing approximately 0.17 mg/mL of the affinity-purified mini-agrin. Wells were blocked after washing in phosphate-buffered saline (PBS) using 4% fetal calf serum, 3% goat serum, and 3% horse serum in PBS containing 0.05% Triton X-100. Serum samples were diluted 1:10 in blocking buffer (100 mL per well) and incubated for 1 hour at 37°C. Unbound protein was removed by repeated washing with 0.05% Triton X-100 in PBS. Horseradish peroxidase-conjugated secondary goat antihuman immunoglobulin G (Invitrogen, Darmstadt, Germany) was used at a concentration of 10 mg/mL to detect bound antibodies. Bound antibodies were visualized after repeated washing by incubating with 3,39,5,59-tetramethylbenzidine. The color reaction was stopped by adding 100 mL 1 M HCl, and the optical density (OD) at 450 nm was determined in triplicates using the PowerWave XS ELISA reader (BioTek Instruments, Bad Friedrichshall, Germany). Nonspecific signal was determined by analyzing wells incubated with the coating buffer alone followed by blocking and incubation with secondary antibody and substrate (referred to as uncoated plates). ODs obtained using uncoated plates were subtracted from the sample ODs. Sera were considered positive for anti-agrin antibodies when the mean value was higher than the mean of the control sera plus 4 times the SD, representing confidence of 99.99%. 5, 9 The concentration of the anti-agrin antibodies in the sera was determined using a standard solution of affinity-purified rabbit anti-human agrin antibodies.
Transfection and staining of 293HEK cells. The cDNA coding for human mini-agrin was subcloned into the pMES vector 16 and used to transfect 293HEK cells. The pMES vector contains an internal ribosomal entry site followed by the enhanced green fluorescent protein. This allows the simultaneous expression of human mini-agrin and enhanced green fluorescent protein and, thus, the identification of transfected cells. Successful expression of mini-agrin was confirmed by Western blotting and staining of transfected cells using anti-agrin antibodies. Lipofectamine (Invitrogen) was used to transfect 293HEK cells followed by immunohistochemical analysis 48 hours later. Cells were stained with antisera from patients with MG (dilution 1:800), with sera from control persons or with a rabbit polyclonal anti-human agrin antiserum as described previously. 8 The anti-human agrin serum was generated by immunizing rabbits with a C-terminal 30-kDa fragment expressed in bacteria and affinity-purified using the Protino Ni-TED 1000 system (Macherey-Nagel). The serum was specific for human agrin as determined by staining of transfected cells and by Western blotting (data not shown). Specimens were analyzed using a Zeiss LSM 710 laser scanning confocal microscope (Zeiss, Oberkochen, Germany). Whole images were processed, and contrast and brightness were adjusted using Adobe Photoshop (version CS3; Adobe, Mountain View, CA).
Immunocytochemistry. Longitudinal cryostat sections of adult
mouse skeletal muscles were obtained from 4% paraformaldehyde immersion-fixed mouse leg muscles. Sections of 12-mm thickness were stained as detailed in reference 17 using the appropriate Alexa488-conjugated secondary goat anti-rabbit or goat antihuman secondary antibody (Molecular Probes; 24 mg/mL final concentration). All secondary antibodies were preabsorbed against immunoglobulin G of other species, eliminating cross-reactivity. The MG sera were used at a concentration of 1:500 or 1:800. Antibodies against mouse agrin served as positive control. 18 NMJs were identified by costaining with Alexa594-conjugated a-bungarotoxin (Invitrogen).
Statistical analysis. To validate the significance of the observed differences, we analyzed simple pairwise comparisons with the Student t test (2-tailed distribution with 2-sample equal variance).
RESULTS
Anti-agrin autoantibodies are present in sera from patients with MG. We analyzed a total of 55 sera, including 30 AChR-and MuSK-seronegative sera, 15 sera with elevated levels of anti-MuSK, and 9 with anti-AChR autoantibodies. They were compared with sera from 16 healthy individuals. Fourteen sera had been shown to contain elevated levels of anti-LRP4 autoantibodies. 8 To investigate whether the sera contained autoantibodies against agrin, an ELISA was established. We calculated a cutoff (0.1 OD units) on the basis of the mean 64 SDs of the OD values from control sera. One control serum showed strong unspecific binding to the uncoated ELISA plates (marked with a circle in figure 1) and was therefore excluded from the statistical analysis. Five sera contained elevated levels of anti-agrin antibodies (figure 1) and were subsequently analyzed in more detail together with 2 additional sera. These 2 additional sera were both negative in the agrin ELISA, but one of them reacted with cells transfected with mini-agrin (see below) and one stained NMJs (see the table for details). Statistical analysis revealed a significant difference in anti-agrin antibody concentration compared with the control sera (p values ,0.05). We observed no statistically significant difference between the control sera and the agrin-seronegative sera. The concentration of anti-agrin antibodies in the 5 sera ranged from 0.045 to 0.12 nM (median: 0.078). Of note, 4 of the 5 agrinpositive sera had previously been tested positive for anti-MuSK antibodies. The fifth serum was from a patient with elevated levels of anti-AChR antibodies that had been initially included in the study as an internal control. Two of the 5 antisera were weakly positive for anti-LRP4 antibodies. 8 A summary of the results is shown in the table. These data demonstrate that some sera from patients with MG contain elevated levels of anti-agrin antibodies, suggesting that agrin is a target for autoantibodies. The coexistence of autoantibodies against MuSK, LRP4, or AChR and against agrin may have an influence on the variability and severity of the clinical phenotype.
Clinical presentation and neurophysiologic examination summary. All patients presented with generalized Levels of anti-agrin antibodies in sera from patients with MG ELISAs for anti-agrin antibodies in myasthenia gravis (MG) sera. Mean optical density readings of triplet measurements from normal healthy volunteer sera (red diamonds) and from MG sera (blue diamonds) are shown after subtraction of the signal obtained using uncoated ELISA plates. The green line indicates the cutoff value, calculated as the mean of the control sera plus 4 times the SD. One control serum (marked with a circle) showed considerable binding to uncoated ELISA plates and was excluded from the statistical analysis. Five MG sera had elevated anti-agrin antibody concentrations that met the criteria for being agrin-positive.
muscle weakness and diplopia. Thymectomy in patient 7224 disclosed thymo-follicular hyperplasia, typically associated with early-onset MG, but no thymoma. Three of the 5 agrin-positive patients were older than 50 years at the time of diagnosis and therefore are regarded as patients with late-onset MG who do not benefit from thymectomy. Accordingly, none of these remaining patients had thymectomy. The MG severity, as determined by the MGFA clinical classification, 13 ranged from IIA to V. Edrophonium testing was positive and the repetitive nerve stimulation was abnormal in all cases tested. One patient (case 8733) had a myasthenic crisis. A summary of the demographic, electrophysiologic, and clinical data, together with the treatment at serum sampling, is shown in the table.
Sera from patients with agrin-seropositive MG label adult mouse NMJs. LRP4-positive MG sera labeled the NMJ. 8 To investigate whether the anti-agrin antibodycontaining sera bind to the NMJ, we stained cryostat sections of adult mouse skeletal muscle. NMJs were identified by their high concentration of AChRs, labeled by Alexa594-conjugated a-bungarotoxin. Antiagrin antibodies (panel B) and 3 of the 5 agrin-positive sera stained the NMJ, although at different intensities. Figure 2 shows 2 representative examples (sera 5660 and 8733 in panels C and D, respectively) that strongly label NMJs at a dilution of 1:800. The staining pattern overlapped with the AChR distribution. In contrast, none of the control sera from healthy subjects stained NMJs (panel A). One serum that reacted with miniagrin transfected cells also stained NMJs (serum 7224 in figure 2E ). These results demonstrate that the antiagrin antibody-containing sera cross-react with mouse tissue and label proteins concentrated at the NMJ. Because all agrin-positive sera also contained antibodies against MuSK, LRP4, or against the AChR, the staining of the NMJ might be due to the autoantibodies against these proteins.
Sera from patients with agrin-seropositive MG react
with mini-agrin-expressing cells. To confirm the results of the ELISA and to investigate the binding of the antibodies specifically to native (i.e., nonfixed and nonplastic-bound) and glycosylated agrin, we tested whether the anti-agrin antibody-containing sera reacted with mini-agrin expressed by transfected 293HEK cells. Sera from healthy volunteers and sera from patients without elevated levels of anti-agrin antibodies showed only weak background staining (figure 3, A-C). In contrast, anti-human agrin antibodies strongly labeled transfected cells (figure 3, D-F). Moreover, 2 of the 5 sera with elevated levels of anti-agrin antibodies reacted weakly but consistently with agrin-expressing 293HEK cells (serum 6796 in panels J-L). One serum (8733) could not be analyzed because of excessive background staining. One serum that was not positive in the ELISA specifically stained agrin-transfected cells and the NMJ (serum 7224, figure 3 , G-I). These results indicate that a minority of patients with MG produce antibodies that bind to native agrin, suggesting that autoantibodies against agrin contribute to the impairment of neuromuscular transmission in MG.
DISCUSSION Mutations in the AGRN gene result in congenital myasthenic syndrome in humans 14, 19 and mice, 20 indicating that interfering with agrin function leads to defects in synaptic transmission at the NMJ. Moreover, MuSK and LRP4, which form the agrinreceptor complex responsible for the formation and maintenance of AChR aggregates at the NMJ, have been shown to be targets of autoantibodies in some MG cases. 5,7-9 Herein, we report that 5 of 54 sera from patients with generalized MG contained elevated levels of autoantibodies to agrin. Our results are in agreement with a preliminary meeting report suggesting the presence of anti-agrin antibodies in patients with MG. 21 This study used a larger group of patients with MG and a more sensitive assay system, likely explaining the higher percentage of anti-agrin antibody-positive sera (15% vs 10% in our study). However, details regarding clinical information, serum antibody concentrations, and screening methods were not reported.
The detection of antibodies was performed using purified mini-agrin in a solid-phase ELISA assay. Miniagrin contains the NtA domain and the N-terminalmost follistatin-like domain fused to the C-terminal 3 domains with similarity to the globular domain of the laminin a chain plus the interspaced EGF-like repeats. This protein is functional regarding the instructive signals for the formation, maintenance, and regeneration at the NMJ because it contains the LRP4-binding and MuSKactivating site as well as the domain interacting with laminin. For example, mini-agrin is sufficient to rescue the defects of an agrin knockout mouse, 15, 22 and overexpression of mini-agrin ameliorates the dystrophic symptoms in a mouse model for congenital muscular dystrophy. 23 However, mini-agrin contains only approximately 50% of the coding sequence of agrin. Therefore, a number of epitopes present in full-length agrin are not present in mini-agrin. In particular, the central domains of agrin that contain the glycosaminoglycan side-chain attachment sites and the O-glycosylation sites as well as most of the follistatin-like domains are not present in the mini-agrin protein. In our ELISA, we therefore might have missed patients with autoantibodies against the central domains of agrin. More patients with agrinseropositive MG might be identified if a full-length agrin protein is used as probe.
Agrin is a heparan sulfate proteoglycan that is expressed in many different tissues. Moreover, agrin is differentially spliced, and only particular isoforms of agrin are synaptogenic at the NMJ. Because the difference between neuronal and nonneuronal agrin isoforms is the presence of short peptides of 8 and/or 11 amino acids, respectively, within the C-terminal globular domain, it is reasonable to assume that the antibodies detected in the sera of patients with MG reacts with all isoforms. This would indicate that the autoantibodies could potentially also react with the agrin isoforms expressed, for example, in kidney or blood vessels. It will be interesting to investigate whether the patients with agrin-seropositive MG have clinical defects that are not associated with NMJs and not present in AChR-seropositive patients. This would indicate additional consequences of the antiagrin antibodies in nonmuscle tissues.
The anti-agrin antibody concentrations in the MG sera determined in this study range between 0.12 and 0.045 nM (see the table). This is considerably lower compared with the antibody titer in AChR-seropositive MG (concentrations between 0.2 and 0.5 nM, range between 0.5 and .1,000 nM 9,24 ) but in the range of MuSK-seropositive MG (antibody concentrations .0.05 nM, range 1-100 nM 25 ) and LRP4seropositive MG (antibody concentration between 0.019 and 2.07 nM 7 ). It should be noted that the antibody concentrations determined in this study are close to the detection limit of the ELISA used for the initial screen. It therefore remains possible that with the use of more sensitive methods, the number of agrin antibodycontaining sera might increase. The selective nature of the sera tested and the low number of patients with agrin-seropositive MG identified in our study also precludes conclusions regarding the prevalence of this serotype within the cohort of patients with MG.
All 5 sera with elevated levels of anti-agrin antibodies had additional antibodies against other proteins of the NMJ: 4 had autoantibodies to MuSK, 1 serum had autoantibodies to AChR, and 2 had autoantibodies to LRP4. This indicates that a high proportion of the sera analyzed had antibodies against multiple NMJ target proteins. The coexistence of autoantibodies to several muscle proteins is more prominent in patients with paraneoplastic MG associated with thymoma, who with few exceptions almost always have autoantibodies to AChR. Accordingly, thymomas in patients with autoantibodies to LRP4 or MuSK are rare. 5, 7 Several previous studies have reported antibodies against more than one protein in the sera of patients with MG, including, for example, AChR and MuSK, 6, 24, 26 LRP4 and MuSK, [7] [8] [9] 21 and LRP4 and AChR. 21 This study reports the coexistence of autoantibodies to MuSK and agrin antibodies in patients with MG and identifies a unique triple-positive patient with autoantibodies against agrin, MuSK, and LRP4.
It is currently unclear whether and how the antiagrin antibodies could contribute to the muscle weakness observed in patients with MG or whether they have resulted, for example, from contact with neoantigenic epitopes from damaged NMJs. A number of antibodies have been detected in sera from patients with MG that apparently do not contribute to the pathogenic or clinical phenotype, including antibodies against titin, the ryanodine receptor, and the voltage-gated potassium channel Kv1.4. 27 The low concentration and the presence of additional autoantibodies in the agrinseropositive patients questions whether they contribute to the myasthenic pathology at all. However, agrin is an essential component of and functionally involved in the development and maintenance of the NMJ. Therefore, it is tempting to speculate that anti-agrin antibodies might interfere with the agrin-LRP4-MuSK pathway leading to a reduced concentration of AChRs at NMJs and subsequent muscle weakness. This hypothesis is in agreement with a preliminary report showing the ability of anti-agrin antibodies in sera from patients with MG to interfere with the agrin-mediated AChR clustering on C2C12 myotubes in culture. 21 The simultaneous presence of anti-MuSK or anti-LRP4 antibodies described in our study, however, precluded a functional analysis. Clearly, a more detailed analysis with a larger cohort of patients is required to elucidate the contribution of antiagrin antibodies to the neuromuscular defects in MG.
